% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, AŞ Message Board

  • billyteex1 billyteex1 Jun 10, 2009 7:36 AM Flag

    Need to watch what

    Need to watch what Celg is talking about and then look hard at what easai didn't talk about. Bet the first thing that pops in your head is what is billyteex1 talking about. I believe Dacogen is maybe in serious trouble holding it's position.

    Press Release Source: Celgene International Srl
    Presentations at the 14th Congress of the European Hematology Association Demonstrate VIDAZA Benefits Patients with Myelodysplastic Syndromes

    Data show VIDAZA extends survival and reduces dependence on blood transfusions

    On Monday June 8, 2009, 1:30 am EDT

    BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG - News) announced that data presented at the 14th Congress of the European Society of Hematology demonstrate that treatment with VIDAZA significantly extends overall survival and helps patients with myelodysplastic syndromes (MDS) become or remain red blood cell transfusion independent. Patients who benefited included those with higher-risk MDS or acute myeloid leukaemia (AML) with 20-30% blasts, as defined by the World Health Organization (WHO).

    “The presentations at EHA this year continue to support the clinical benefit associated with VIDAZA in MDS, including significantly extended overall survival, and add to the data from the international AZA-001 survival study published in The Lancet Oncology earlier this year,” said Jean-Pierre Bizzari, Senior Vice President and Group Head of Global Oncology/Hematology of Celgene. “Additionally, they reinforce the significant and durable transfusion independence provided by VIDAZA, which is associated with improved overall survival in this difficult to treat group of diseases.”

    Azacitidine (AZA) improves overall survival in WHO acute myeloid leukaemia (AML) in elderly patients with low bone marrow blast counts

    A sub-analysis of the AZA-001 survival trial sought to confirm and further elucidate a positive overall survival trend shown by a subset of patients in an earlier phase III study (CALGB 9221) comparing VIDAZA against best supportive care in patients with WHO-defined AML with blasts <30%.

    Patients with higher-risk MDS classifications (FAB: RAEB, RAEB-t, CMML and IPSS: Int-2 or High) were enrolled and randomised either to VIDAZA therapy or conventional care regimens (CCR: best supportive care, low dose ara-C or intensive chemotherapy).

    Of 358 patients, 113 (32%) met WHO AML criteria (median 23% marrow blasts). Subsequently, 55 were randomised to VIDAZA and 58 to CCR. Of the 58 CCR patients, 47 percent were treated with best supportive care, 34 percent with low-dose ara-C and 19 percent with intense chemotherapy.

    In the study, at two years, 50 percent of patients in the VIDAZA group were alive compared to 16 percent of those in the CCR group (p=0.0007). The median overall survival was 24.5 and 16.0 months in the VIDAZA and CCR groups, respectively, (HR=0.47 [95%CI: 0.28-0.79], p=0.004).

    “As shown with higher-risk MDS patients in the AZA-001 study, patients with WHO-defined AML treated with VIDAZA also demonstrate an improved overall survival rate compared to conventional care regimens,” said Prof. Valeria Santini of Policlinico di Careggi, in Florence, Italy. “This also supports the trend shown in the CALGB 9221 study.”

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • What has the annual meeting produced in the way of talking points for us bagholders?

    • Need to watch what Celg is talking about and then look hard at what easai didn't talk about. Bet the first thing that pops in your head is what is billyteex1 talking about. I believe Dacogen is maybe in serious trouble holding it's position.

      Don't listen to this fricken moron. Wait until we come across the solar ecilpse when the dry earth become fertile once again. We we run to all new high for I have spoken my loyal subjects. No white jackets for me, just praise for I have given you anoher one.

    • It is going on now. It started about 25 minutes ago. It is today June 11, 2009 at 2:00pm PDT, 5:00 pm EDT.

    • Supg's holding up well. I still remain positive, I like that the CMO still holds 400K shares and if he believes I believe. When is the annual meeting?

    • Isn't thi sjust more of CELG pumping it's survival benefit? Old news. Other indications might be new news but it does not effect current Dacogen.

      • 1 Reply to f8ful
      • No, they are pointing at aml patients showing benefits now and head to head data on dac/vidaza. This is what bothers me, Easai has 400 representives out there in the field, so to not give any guidance on Dacogen is a red flag that they're not seeing the sales that they once had. Dacogen held it's own, only because of additional cycles, but what I think is happening right now is that md's are better understanding the slower acting vidaza needs time to show superior benefits. They maybe enrolling a mjority of new patients with vidaza.

        I'm open to any logical explaination on easai not giving guidance. (mero I said logical). I'm prepared for a bumpy ride and glad that a few more this time are here to discuss what's developing. I would not be surprised if Dacogen sales head towards 10M a quarter from the 40M. Dr. Manuso stated last year at this time S110 would be in the clinics by 4Q08, but now 1H10. He needs to explain all the delays.